Skip to main content
. 2021 May 26;48(1):138. doi: 10.3892/ijmm.2021.4971

Figure 1.

Figure 1

High LBX2-AS1 expression is a promising diagnostic and prognostic biomarker for patients with colorectal cancer. (A) Heatmap depicting aberrantly expressed lncRNAs between 10 pairs of colorectal cancer specimens and normal specimens. Red, upregulation; green, downregulation. (B) The difference in expression pattern of LBX2-AS1 between colorectal cancer samples and normal samples from TCGA database. (C) The difference in LBX2-AS1 expression among different clinical stages of colorectal cancer from TCGA database. (D) Box plots showing the expression levels of LBX2-AS1 between colorectal cancer and normal tissues from a total of 145 colorectal cancer cohort according to RT-qPCR. (E) Box plots showing the difference in LBX2-AS1 expression between stage III-IV and I-II. **P<0.01. (F) RT-qPCR results demonstrated high LBX2-AS1 expression in colorectal cancer cell lines. **P<0.01 vs. FHC cells. (G) AUC of receiver operating characteristic curve was 0.7595 and P<0.0001, indicating a high sensitivity and accuracy of LBX2-AS1 for colorectal cancer diagnosis. In TCGA database, LBX2-AS1 expression was associated with (H) OS, but not (I) DFS. (J and K) Among 145 patients with colorectal cancer, LBX2-AS1 expression had a positive association with poorer OS and DFS. LBX2-AS1, LBX2 antisense RNA 1; lncRNA, long non-coding RNA; TCGA, The Cancer Genome Atlas; RT-qPCR, reverse transcription-quantitative PCR; AUC, area under the curve; OS, overall survival; DFS, disease-free survival; GEPIA, Gene Expression Profiling Interactive Analysis.